Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Effects of hypoxic and photobiomodulation preconditioning on mesenchymal stem cell-derived exosomes: an in vitro study with an osteogenic potential approach.

Khosravipour A., Ebrahimzadeh MH., Mousavi Shaegh SA., M Matin M., Ebrahimzadeh-Bideskan A.

Laboratory Study on Immune Modulation, published in Photochem Photobiol Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Photochem Photobiol Sci (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41239027
DOI
10.1007/s43630-025-00810-y

Abstract (original English)

Mesenchymal stem cell-derived exosomes (MSC-Exos) have emerged as promising therapeutic agents for bone regeneration due to their regenerative and immunomodulatory properties. This study investigates the effects of hypoxic and Photobiomodulation (PBM) preconditioning on the characteristics and functional properties of exosomes derived from human adipose-derived mesenchymal stem cells (hAdMSCs), with a focus on bone regeneration. hAdMSCs were characterized by their spindle-shaped morphology and high expression of mesenchymal markers (CD73: 99.6%, CD105: 99.9%) and minimal expression of hematopoietic and endothelial markers (CD45: 0.2%, CD31: 2.25%). Exosomes were isolated from hAdMSCs cultured under normal (N-EX), hypoxic (H-EX), PBM (PBM-EX), and combined PBM + hypoxia (PBM + H-EX) conditions. Exosomal markers (CD9, CD63, and CD81) and size distribution (72.2-88.4 nm) confirmed successful isolation, with no significant differences in size between different groups. Functional assays revealed that a 200 µg exosome dose significantly enhanced cell proliferation and metabolic activity (p < 0.0001). Exosome-treated groups exhibited significantly enhanced cell viability, maintained stable glucose uptake, and accelerated migration compared to control groups. Notably, the PBM-EX group demonstrated the most remarkable outcomes, achieving complete scratch closure within just 20 h. Osteog

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ExosomesMesenchymal Stem CellsHumansOsteogenesisCell ProliferationCells, CulturedLow-Level Light TherapyCell HypoxiaCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research